Haloperidol Neuraxpharm

Haloperidol Neuraxpharm is an injectable formulation of the butyrophenone antipsychotic haloperidol. Marketed in the European Union, this prescription product is supplied as an intramuscular solution (strength not specified). It acts as a dopamine D2 receptor antagonist and is used under medical supervision for psychiatric conditions. The medication is manufactured by Neuraxpharm and distributed to hospitals for acute management of psychotic episodes in inpatient care settings.

Haloperidol Neuraxpharm is indicated for the short‑term treatment of several acute psychiatric conditions.

- Schizophrenia, particularly when rapid symptom control is required. - Acute psychotic episodes associated with mood disorders or substance use. - Severe agitation or aggression in patients with established psychotic disorders. - Pre‑operative sedation in patients at risk of delirium.

Side effects of Haloperidol Neuraxpharm vary in frequency and severity.

Common: - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Drowsiness or sedation. - Dry mouth and increased salivation. - Constipation or gastrointestinal discomfort.

Serious: - Neuroleptic malignant syndrome, a rare but life‑threatening reaction. - Torsades de pointes or other significant cardiac arrhythmias.

Clinicians should consider several precautions before prescribing Haloperidol Neuraxpharm.

- Assess cardiovascular status, especially QT interval, prior to initiation. - Use the lowest effective dose for the shortest duration needed. - Monitor for signs of extrapyramidal reactions and adjust therapy accordingly. - Evaluate hepatic and renal function in patients with organ impairment. - Avoid use in patients with known hypersensitivity to haloperidol or other butyrophenones. - Caution in pregnant or breastfeeding individuals; risk–benefit assessment is required.

Haloperidol Neuraxpharm can interact with other medications that affect the central nervous system or cardiac conduction.

Avoid: - Other dopamine antagonists or high‑potency antipsychotics, which may increase extrapyramidal risk. - Drugs that prolong the QT interval, such as certain antiarrhythmics, macrolide antibiotics, or fluoroquinolones. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can raise haloperidol plasma levels.

Use with caution: - CNS depressants including benzodiazepines or opioids, which may enhance sedation. - CYP3A4 inducers (e.g., rifampin, carbamazepine) that may reduce therapeutic effect.